Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.73 |
| ▸ | ITGAV | P06756 | 18/20 | 0.73 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.73 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382704 | 0.98 | ITGB3 (0.70) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL382937 | 0.95 | ITGB3 (0.66) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6498837 | 0.92 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7461042 | 0.92 | ITGB3 (0.74) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6496357 | 0.90 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL382329 | 0.89 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL381996 | 0.89 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6497483 | 0.89 | ITGB3 (0.60) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6495965 | 0.88 | ITGB3 (0.58) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL382754 | 0.88 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1074543-B1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA PHARMA CO LTD (JP) | 2012-01-25 | — | — | EP | claimed |
| US-6420558-B1 | COMPOUNDS WITH AMIDINE GROUPS ANTAGONISTIC ACTIVITY, CELL ADHESION INHIBITORY ACTIVITY, HUMAN PLATELET AGGREGATION INHIBITORY ACTIVITY, AND THERAPEUTIC AGENTS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-16 | — | — | US | claimed |
| EP-1074543-A1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2001-02-07 | — | — | EP | claimed |
| EP-1074543-B1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA PHARMA CO LTD (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1250935-A1 | REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| US-6420558-B1 | COMPOUNDS WITH AMIDINE GROUPS ANTAGONISTIC ACTIVITY, CELL ADHESION INHIBITORY ACTIVITY, HUMAN PLATELET AGGREGATION INHIBITORY ACTIVITY, AND THERAPEUTIC AGENTS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1074543-A1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.